Evogene Subsidiary Ag Plenus Appoints Dr. Dan Jacob Gelvan as CEO

TL;DR

**Evogene's subsidiary Ag Plenus just named Dr. Dan Jacob Gelvan as its new CEO, signaling a potential shift in their crop protection strategy.**

AI Summary

Evogene Ltd. announced on February 22, 2024, changes in the management of its subsidiary, Ag Plenus Ltd. Dr. Dan Jacob Gelvan will be appointed as the new Chief Executive Officer of Ag Plenus. This change is part of Evogene's strategy to advance its sustainable crop protection products.

Why It Matters

This management change at Ag Plenus could impact the strategic direction and development of novel sustainable crop protection products, potentially affecting Evogene's market position in agricultural chemicals.

Risk Assessment

Risk Level: low — The filing only announces a management change, which is a routine corporate event and does not inherently carry significant immediate financial risk.

Key Players & Entities

• Evogene Ltd. (company) — Registrant announcing management changes
• Ag Plenus Ltd. (company) — Subsidiary of Evogene Ltd. experiencing management changes
• Dr. Dan Jacob Gelvan (person) — Appointed as Chief Executive Officer of Ag Plenus Ltd.
• February 2024 (date) — Month of report
• 001-36187 (company) — Commission File Number for Evogene Ltd.

FAQ

Filing Documents

• zk2431033.htm (6-K) — 13KB
• exhibit_99-1.htm (EX-99.1) — 14KB
• image00002.jpg (GRAPHIC) — 3KB
• image00003.jpg (GRAPHIC) — 2KB
• 0001178913-24-000687.txt ( ) — 35KB

From the Filing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2024 Commission File Number: 001-36187 EVOGENE LTD. (Translation of Registrant's Name into English) 13 Gad Feinstein Street, Park Rehovot, Rehovot P.O.B 4173, Ness Ziona, 7414002, Israel (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F CONTENTS Changes in Management Evogene Ltd., or Evogene, today announces changes in the management of its subsidiary, Ag Plenus Ltd., or Ag Plenus, a global leader in designing and developing novel sustainable crop protection products: Dr. Dan Jacob Gelvan will be appointed as Chief Executive Officer, or CEO, of Ag Plenus effective as of February 19, 2024. A copy of the press release is furnished as Exhibit 99.1 to this Report of Foreign Private Issuer on Form 6-K, or this Form 6-K. The content of Exhibit 99.1 to this Form 6-K, excluding the statement of the incoming CEO of Ag Plenus and of the CEO of Evogene, is incorporated by reference into the registration statements on Form F-3 (File No. 333-253300 ) and on Form S-8 (File Nos. 333-193788, 333-201443, 333-203856 and 333-259215 ) of Evogene, filed with the Securities and Exchange Commission, to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Date: February 22, 2024 EVOGENE LTD. (Registrant) By: /s/ Yaron Eldad Yaron Eldad Chief Financial Officer EXHIBIT INDEX EXHIBIT NO. DESCRIPTION 99.1 Press Release: AgPlenus Announces Appointment of Dr. Dan Jacob Gelvan as its Incoming Chief Executive Officer

View Full Filing

View this 6-K filing on SEC EDGAR